Specialty
Cataract & Refractive Dermatology General Ophthalmology Glaucoma Neurology Optometry Retina Women's Health View All Courses
Course Type
Supplement Webinar In-person View All Courses
Search
Login

Treating Retinal Disorders: Updates for the Newer Retina Specialist Live Meeting

By: Disher Dhoot, MD; Amir Kashani, MD; Andrew Moshfeghi, MD, MBA; Rishi Singh, MD; Nathan Steinle, MD; Veeral S. Sheth, MD, MBA, FACS; Charles C. Wykoff, MD, PhD

In Person Credits: 4

Expiration Date: Sunday, June 30, 2019
Release Date: June 2018

Learning Objectives

Upon completion of this activity, the participant should be able to:

Discuss recent studies that address long-term treatment outcomes in age-related macular degeneration (AMD)

Develop an individualized treatment plan for patients with AMD

Discuss implementing imaging tools as diagnostic therapies

Summarize the outcomes of pivotal studies in AMD and DME and how study results may differ from “real-world” dosing methods

Summarize the head-to-head-to-head Protocol T findings in DME and how to relate that to clinical practice patterns

Evaluate practice flow to determine the most efficient patient experience

Develop plans to reduce reimbursement denials

Accreditation and Designation Statement

Accreditation Statement
Evolve Medical Education LLC (Evolve) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Evolve designates this live activity for a maximum of 4 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Faculty and Disclosures

Disher  S. Dhoot, MD,  has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alimera Sciences; Allergan plc; Genentech; Notal Vision;  Regeneron Pharmaceuticals, Inc . and Santen.  Advisory Board/Speaker’s Bureau: Alimera Sciences; Genentech; and Regeneron Pharmaceuticals, Inc.

Amir H. Kashani, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of  Grant/Research Support: Carl Zeiss Meditec;  and Regenerative Patch Technologies, Inc.

Andrew A. Moshfeghi, MD, MBA, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant:  Allergan plc; Genentech, Inc; and Regeneron Pharmaceuticals Inc. Grant/Research Support:  Genentech, Inc; and Regeneron Pharmaceuticals, Inc.

Rishi P. Singh, MD,  has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau:  Carl Zeiss Meditec; Genentech, Inc; Optos plc; and Regeneron Pharmaceuticals, Inc. Grant/Research Support:  Apellis Pharmaceuticals; Clearside Biomedical; Genentech, Inc; Novartis AG; and Regeneron Pharmaceuticals, Inc.

Nathan Steinle, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alimera Sciences; Genentech; Notal Vision; and Vortex Surgery. Advisory Board/Speaker’s Bureau: Genentech; and Regeneron Pharmaceuticals, Inc. Grant/Research Support: Carl Zeiss Meditec;  Genentech; and Regeneron Pharmaceuticals, Inc.

Verral S. Sheeth, MD, MBA, FACS,  has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Speaker’s Bureau:  Alimera Sciences; Genentech, Inc; Mallinckrodt; and Notal Vision. Grant/Research Support:  Alimera Sciences; Allergan Inc; Genentech, Inc; and Regeneron Pharmaceuticals, Inc.

Editorial Support Disclosures
Erin K. Fletcher, MIT, director of compliance and education, Evolve; and Michelle Dalton, writer, have no financial relationships with commercial interests. Jaya Kumar, MD, peer reviewer, has no financial relationships with commercial interests.

Disclaimer

The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Regeneron Pharmaceuticals, Inc.

OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Pretest

Test

Instructions

Step 1 of 3

33%
  • AgreeNeutralDisagree
    Discuss recent studies that address long-term treatment outcomes in AMD
    Develop an individualized treatment plan for patients with AMD
    Discuss implementing imaging tools as diagnostic therapies
    Summarize the outcomes of pivotal studies in AMD and DME and how study results may differ from “real-world” dosing methods
    Summarize the head-to-head-to-head Protocol T findings in DME and how to relate that to clinical practice patterns.
    Evaluate practice flow to determine the most efficient patient experience.
    Develop plans to reduce reimbursement denials
Back